Stanislaw B.
- Country
- Poland
- Department
- N/A
Research Overview
- Randomised study for double-blind, placebo-controlled evaluation of BI 765845 on top of standard of care in patients with myocardial infarction
- A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)
- Efficacy of Evolocumab Versus Standard Care in LDL-C Reduction for Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention
Data & Insights
Has run more than one trial at 223 of 670 partner sites.
Specializations
Cardiovascular Disease Management
Specializes in investigating innovative treatments for acute myocardial infarction and its various presentations, including both STEMI and NSTEMI conditions. Focuses on developing therapeutic strategies for post-infarction care and prevention of recurrent cardiac events.
- ST-Elevation Myocardial Infarction (STEMI)
- Non-ST-Elevation Myocardial Infarction (NSTEMI)
- Post-infarction Treatment Optimization
Cardiovascular Risk Management
Conducts research in atherosclerotic cardiovascular disease and hypertension management. Investigates novel therapeutic approaches including renal denervation techniques and lipid-modifying therapies for cardiovascular risk reduction.
- Coronary Plaque Management
- Blood Pressure Control Strategies
- Lipid Management Therapies
Cardiac Complications
Explores treatments for atrial fibrillation and associated conditions, with particular attention to patients unsuitable for conventional anticoagulation. Additionally investigates iron deficiency in cardiac patients and its impact on cardiovascular outcomes.
- Anticoagulation Alternatives
- Iron Deficiency Management
- Stroke Prevention Strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.